Alessandro Bartolomucci Selected Research

Alessandro Bartolomucci Research Topics

Disease

15	Obesity 11/2023 - 11/2011
8	Body Weight (Weight, Body) 08/2021 - 07/2010
4	Inflammation (Inflammations) 12/2023 - 10/2016
4	Neoplasms (Cancer) 01/2022 - 04/2007
3	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2024 - 05/2020
3	Hypertension (High Blood Pressure) 01/2022 - 10/2016
3	Hyperphagia (Overeating) 08/2021 - 08/2011
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2023 - 10/2016
2	Insulin Resistance 01/2023 - 01/2016
2	Cardiotoxicity 01/2022 - 01/2018
2	Heart Failure 01/2022 - 01/2018
2	Type 2 Diabetes Mellitus (MODY) 01/2020 - 01/2016
2	Pain (Aches) 12/2011 - 08/2008
1	Wasting Syndrome (Wasting Disease) 01/2024
1	Anaphylaxis (Anaphylactic Shock) 12/2023
1	Metabolic Diseases (Metabolic Disease) 12/2023
1	Weight Loss (Weight Reduction) 12/2023
1	Fatty Liver 11/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Dementia (Dementias) 01/2022
1	Hypertrophy 01/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2019
1	Muscle Weakness 11/2018
1	Cardiomegaly (Heart Hypertrophy) 01/2018
1	Hyperglycemia 10/2016
1	Facioscapulohumeral Muscular Dystrophy 01/2016
1	Insulinoma 06/2015
1	Glucose Intolerance 05/2015
1	Binge-Eating Disorder (Binge Eating Disorder) 01/2015
1	Dyslipidemias (Dyslipidemia) 12/2013
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2012
1	Fibrosis (Cirrhosis) 01/2012
1	Lymphopenia (Lymphocytopenia) 04/2007
1	Infections 09/2004

Drug/Important Bio-Agent (IBA)

7	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 12/2011
6	Peptides (Polypeptides)IBA 01/2017 - 08/2008
4	LipidsIBA 11/2023 - 01/2016
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2018
3	DystrophinIBA 01/2024 - 11/2018
3	Angiotensin IIIBA 01/2022 - 10/2016
3	NeuropeptidesIBA 08/2021 - 01/2017
3	CorticosteroneIBA 01/2021 - 07/2010
3	LeptinIBA 05/2015 - 11/2011
2	Proteins (Proteins, Gene)FDA Link 01/2024 - 01/2022
2	Biomarkers (Surrogate Marker)IBA 12/2021 - 12/2011
2	Blood Glucose (Blood Sugar)IBA 08/2021 - 10/2016
2	Complement C3a (Complement 3a)IBA 09/2019 - 01/2017
2	ChromograninsIBA 01/2013 - 12/2011
1	complement C3a receptorIBA 12/2023
1	LigandsIBA 12/2023
1	RNA (Ribonucleic Acid)IBA 11/2023
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2023
1	DNA AdductsIBA 12/2021
1	doxorubicin-DNAIBA 12/2021
1	Peptide Receptors (Peptide Receptor)IBA 09/2019
1	Angiotensin Receptor AntagonistsIBA 01/2019
1	ResveratrolIBA 01/2018
1	p38 Mitogen-Activated Protein KinasesIBA 01/2018
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2017
1	CytokinesIBA 10/2016
1	Insulin (Novolin)FDA Link 01/2016
1	Transcription Factors (Transcription Factor)IBA 01/2016
1	Leptin ReceptorsIBA 05/2015
1	AdiponectinIBA 12/2013
1	chromogranin A (344-364)IBA 01/2013
1	Chromogranin AIBA 01/2013
1	Serotonin (5 Hydroxytryptamine)IBA 01/2012
1	Muscarinic M2 ReceptorIBA 01/2012
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2012
1	Adrenergic Receptors (Adrenergic Receptor)IBA 01/2012
1	Neuropeptide YIBA 11/2011
1	Sildenafil Citrate (Viagra)FDA Link 01/2011
1	Formaldehyde (Formol)FDA Link 08/2008
1	Messenger RNA (mRNA)IBA 08/2008
1	AntigensIBA 04/2007
1	Immunoglobulin G (IgG)IBA 04/2007
1	Tuberculin (PPD)IBA 09/2004
1	Interleukin-10 (Interleukin 10)IBA 09/2004

Therapy/Procedure

5	Drug Therapy (Chemotherapy) 12/2021 - 01/2016
3	Therapeutics 12/2023 - 01/2017
2	Gastrectomy 12/2023 - 11/2023
2	Investigational Therapies (Experimental Therapy) 01/2017 - 01/2015
1	Bariatric Surgery 12/2023
1	Gastric Bypass (Roux-en-Y Gastric Bypass) 12/2023
1	Controlled Hypotension 01/2021
1	Denervation 10/2016
1	Fat-Restricted Diet (Diet, Fat Restricted) 10/2016